My laboratory interests include experimental therapeutics in CLL with a focus on signaling pathways and kinase inhibition.  I am especially interested in BTK inhibitors, resistance mechanisms associated with BTK inhibitors, and strategies to overcome resistance. Our group has characterized the first group of patients resistant to ibrutinib and discovered novel mutations in the B cell receptor signaling pathway which confer resistance to this agent. I lead preclinical and clinical endeavors to identify risk factors for the development of resistance to BTK inhibitors and explore novel pathways to prevent or circumvent resistance.

Woyach Lab Webpage